Carlos F. Barbas0000-0003-2360-7190
Carlos F. Barbas received his Ph.D. in organic chemistry from Texas A&M University in 1989 working with Chi-Huey Wong. Following postdoctoral studies at Pennsylvania State University and The Scripps Research Institute, he was appointed Assistant Professor in 1991 at The Scripps Research Institute where he is now the Janet and W. Keith Kellogg II endowed Professor of Chemistry and Molecular Biology. Dr. Barbas has published approximately 300 scientific articles and is a named inventor on over 50 issued U.S. patents. Dr. Barbas has received honors including the Investigator Award from the Cancer Research Institute, the Scholar Award of the American Foundation for AIDS Research, the American Chemical Society Cope Scholar Award, and the Tetrahedron Young Investigator Award for Bioorganic and Medicinal Chemistry. He is the founder of the biotechnology companies Prolifaron (acquired by Alexion Pharmaceuticals in 2000), CovX (acquired by Pfizer in 2008), and Zyngenia Inc. and the inventor of their underlying core technologies. His inventions have facilitated the creation of a variety of novel drugs in a number of therapeutic areas.
Biography Updated on 31 July 2013